Oryzon Genomics has announced that the European Medicines Agency (EMA) has provided regulatory clearance for a Phase Ib trial of iadademstat in sickle cell disease. The Phase Ib study (named RESTORE) is expected to enrol 40 adult patients with the condition, and will be based across multiple sites
